Fig. 6From: Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapyResults of tumor-infiltrating immune cell analysis using CIBERSORT. A The proportion of tumor-infiltrating immune cell (TIIC) in CCL19 low-expression (above) and high-expression (below) groups. B Correlation of TIIC subtypes and CCL19 expression. TIIC: tumor-infiltrating immune cellBack to article page